Atai Beckley (9VC) Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
9VC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Atai Beckley N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.84 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$1.06 |
| Beta | 1.6 |
| 1 Month Change | -13.20% |
| 3 Month Change | 10.42% |
| 1 Year Change | 176.40% |
| 3 Year Change | 31.56% |
| 5 Year Change | n/a |
| Change since IPO | -64.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9VC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -19.4% | -1.2% | -0.9% |
| 1Y | 176.4% | -17.8% | 11.5% |
Return vs Industry: 9VC exceeded the German Pharmaceuticals industry which returned -17.8% over the past year.
Return vs Market: 9VC exceeded the German Market which returned 9.8% over the past year.
Price Volatility
| 9VC volatility | |
|---|---|
| 9VC Average Weekly Movement | 12.4% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9VC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9VC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 54 | Srini Rao | www.ataibeckley.com |
Atai Beckley N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.
Atai Beckley N.V. Fundamentals Summary
| 9VC fundamental statistics | |
|---|---|
| Market cap | €809.57m |
| Earnings (TTM) | -€103.44m |
| Revenue (TTM) | €2.00m |
Is 9VC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9VC income statement (TTM) | |
|---|---|
| Revenue | US$2.31m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.31m |
| Other Expenses | US$121.71m |
| Earnings | -US$119.40m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,171.24% |
| Debt/Equity Ratio | 6.0% |
How did 9VC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/10 14:45 |
| End of Day Share Price | 2025/11/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atai Beckley N.V. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Bouchey | Aegis Capital Corporation |
| Harry Gillis | Berenberg |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |